Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (161-170 of 254) with videos related to

Pageof 26
Sort By:
Diabetes Care|December 3, 2017
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic DiseaseBrian A Bergmark, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|September 25, 2019
Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical TrialDaniela Jakubowicz, Zohar Landau, Shani Tsameret, et al.
Diabetes Care|February 28, 2009
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trialItamar Raz, Peter W F Wilson, Krzysztof Strojek, et al.
Diabetes Care|September 16, 2016
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert ForumWilliam T Cefalu, John B Buse, Jaakko Tuomilehto, et al.
Diabetes Care|June 11, 2014
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptinItamar Raz, Deepak L Bhatt, Boaz Hirshberg, et al.
Diabetes Care|January 28, 2021
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER TrialFrederik Persson, Stephen C Bain, Ofri Mosenzon, et al.
Plos One|December 2, 2015
Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 DiabetesNathalie Assayag-Asherie, Dror Sever, Marika Bogdani, et al.
JAMA Cardiology|December 8, 2017
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 TrialBenjamin M Scirica, Ofri Mosenzon, Deepak L Bhatt, et al.
Circulation|August 1, 2019
Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 TrialBrian A Bergmark, Deepak L Bhatt, Darren K McGuire, et al.
Diabetes, Obesity & Metabolism|July 4, 2020
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trialOfri Mosenzon, Stephen C Bain, Hiddo J L Heerspink, et al.
Pageof 26

Showing results (161-170 of 254) with videos related to

Sort By:
Pageof 26
Diabetes Care|December 3, 2017
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic DiseaseBrian A Bergmark, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|September 25, 2019
Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical TrialDaniela Jakubowicz, Zohar Landau, Shani Tsameret, et al.
Diabetes Care|February 28, 2009
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trialItamar Raz, Peter W F Wilson, Krzysztof Strojek, et al.
Diabetes Care|September 16, 2016
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert ForumWilliam T Cefalu, John B Buse, Jaakko Tuomilehto, et al.
Diabetes Care|June 11, 2014
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptinItamar Raz, Deepak L Bhatt, Boaz Hirshberg, et al.
Diabetes Care|January 28, 2021
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER TrialFrederik Persson, Stephen C Bain, Ofri Mosenzon, et al.
Plos One|December 2, 2015
Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 DiabetesNathalie Assayag-Asherie, Dror Sever, Marika Bogdani, et al.
JAMA Cardiology|December 8, 2017
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 TrialBenjamin M Scirica, Ofri Mosenzon, Deepak L Bhatt, et al.
Circulation|August 1, 2019
Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 TrialBrian A Bergmark, Deepak L Bhatt, Darren K McGuire, et al.
Diabetes, Obesity & Metabolism|July 4, 2020
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trialOfri Mosenzon, Stephen C Bain, Hiddo J L Heerspink, et al.
Pageof 26